Evangelos S. Gragoudas

Evangelos S. Gragoudas

Auto-generated profile, based on publicly available information

Evangelos S. Gragoudas

Massachusetts Eye and Ear Infirmary/Harvard Medical School

Research Focus & Metrics

Academic Career Length

42Years (1985-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
30 December 2004 in New England Journal of Medicine
Verified
Journal Article
Closed access
PDF file
EGEvangelos S. Gragoudas
Evangelos S. Gragoudas
AAAnthony P. Adamis
Anthony P. Adamis
ECEmmett T. Jr. Cunningham
Emmett T. Jr. Cunningham
MFMatthew Feinsod
Matthew Feinsod
DGDavid R. Guyer
David R. Guyer
Pegaptanib, an anti–vascular endothelial growth factor therapy, was evaluated in the treatment of neovascular age-related macular degeneration.

1 July 2014 in Experimental Eye Research
Verified
Journal Article
Closed access
KBKatarzyna Brodowska
Katarzyna Brodowska
AAAhmad Al-Moujahed
Ahmad Al-Moujahed
AMAnna Marmalidou
Anna Marmalidou
MHMelissa Meyer zu Horste
Melissa Meyer zu Horste
JCJoanna Cichy
Joanna Cichy
DVDemetrios G. Vavvas
Demetrios G. Vavvas

1 December 2002 in Archives of Ophthalmology (1950)
Verified
Journal Article
Open access
PDF file
EGEvangelos Gragoudas
Evangelos Gragoudas
WLWenjun Li
Wenjun Li
MGMichael Goitein
Michael Goitein
ALAnne Marie Lane
Anne Marie Lane
JMJohn E. Munzenrider
John E. Munzenrider
KEKathleen M. Egan
Kathleen M. Egan
UVEAL MELANOMA is an uncommon intraocular malignancy, occurring in fewer than 2000 new patients in the United States each year.1 It is the only intraocular disease that is commonly fatal. Until the introduction of radiation therapy in the 1960s, enucleation was the standard therapy for ocular melanoma. However, a variety of alternative approaches have been attempted in an effort to salvage the eye while eradicating the primary tumor.2-10 Among these, radiation therapy has the widest applicability. The 2 major forms of radiation therapy used in the treatment of these tumors are brachytherapy, in which radiation is delivered through a radioactive plaque sutured to the sclera over the base of the melanoma, and external beam irradiation using proton and helium ion beams.

1 September 2018 in JAMA Ophthalmology
Verified
Journal Article
Closed access
PDF file
ALAnne Marie Lane
Anne Marie Lane
IKIvana K Kim
Ivana K Kim
EGEvangelos S. Gragoudas
Evangelos S. Gragoudas
Importance Despite high rates of local tumor control in patients who are treated for uveal melanoma, most patients will eventually die of metastasis. When metastasis develops, the liver is involved in most cases, and hepatic metastases are particularly refractory to treatment. Finding effective treatments has been challenging. A comparison of survival rates in patients who were treated for metastasis over approximately 30 years may offer insights into progress that has been made in prolonging survival. Objective To compare survival after treatment for metastasis in a cohort of patients who were treated for uveal melanoma at the Massachusetts Eye and Ear Infirmary (MEE) during an approximately 30-year period with an earlier analysis to determine if there was meaningful improvement in survival rates after treatment for metastasis. Design, Setting, and Participants This review included patients (n = 661) who received a diagnosis of metastasis from uveal melanoma who were identified from a cohort of 3063 patients treated at MEE between January 1982 and December 2009 and followed up through December 2011. They were compared with findings from a previous study of patients treated between 1975 and 1987. Main Outcomes and Measures Survival rates in patients who received treatment for metastasis were compared with those who did not receive treatment. The differences in survival rates were compared with an earlier analysis that was completed at MEE. A comparison of patients with hepatic metastases and extrahepatic metastases was also completed. Kaplan-Meier analysis was used to calculate survival rates and the log rank test was used to test for statistically significant differences between the groups. Results Of 620 patients with race information available, 615 (97.3%) were white; the mean (SD) age of patients was 59.71 (13.23) years and 307 (47.3%) were women. The median time from the initial treatment of the tumor to metastasis was 3.45 years (interquartile range [IQR], 2.0-5.57). Overall, the median survival time was poor (3.9 months [IQR, 1.6-10.1]). Patients who received treatment fared better than those who did not receive treatment (median survival after metastasis diagnosis, 6.3 months [IQR, 2.96-14.41] vs 1.7 months [IQR, 0.66-3.5]). This finding was similar to that of our earlier study in which median survival was 5.2 months and 2 months for treated and untreated patients, respectively. Conclusions and Relevance These findings suggest that advances in treatments that lead to clinically meaningful improvements in survival times have not been realized. Similar survival rates in patients who were treated for metastasis were observed in this recent analysis compared with our earlier study. Adjuvant therapies that are initiated at the time of melanoma diagnosis may be the most effective way to prolong survival.

1 November 2006 in Investigative Ophthalmology & Visual Science
Verified
Journal Article
Closed access
PDF file
EGEvangelos S. Gragoudas
Evangelos S. Gragoudas

1 March 2005 in Ophthalmology Clinics of North America
Verified
Journal Article
Closed access
EGE Gragoudas
E Gragoudas
AMA Marielane
A Marielane